Cheap Prescription Drugs in U.S. Can Have Hidden Cost - Bloomberg
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva recalls one lot of leukemia med after finding particulates in vial | Fierce Pharma
Teva Stops Production At US Plant After FDA Concerns: Report
FDA to share full inspection reports with EU; Difficult week for Teva, J&J, Mylan | Teva, Radio, Difficult
Teva Recalls Drug Vials, Shuts Facility Over Mold Concerns - TheStreet
Teva confirms US FDA warning letter for Hangzhou, China API plant
Teva months from restarting production at Hungary plant banned by US FDA
Teva Recalls U.S.-Made Drugs Following Contamination Fears - Bloomberg
FDA Bans Imports From Teva's Hungary Plant Except Two Drugs in Shortage | RAPS
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Filling errors, counterfeit packs gain FDA's attention | Healthcare Packaging
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Celltrion FDA warning causes headache for Teva's biologics ambition
Teva expects FDA preapproval inspection of troubled Celltrion plant this year | Fierce Pharma
Teva Lists Irvine Facilities; Industrial Redevelopment Likely - Orange County Business Journal
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
FDA approves Teva movement disorder treatment - Globes
Teva Earns First FDA Approval for Generic Drug for Major Depressive Disorder | 2019-10-10 | FDAnews
UPDATED: Teva's struggling sterile plant hit with FDA warning letter | Fierce Pharma
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva's struggling sterile plant hit with FDA warning letter - Skyland Analytics
Teva Recalls One Lot Of IDArubicin Hydrochloride Injection
Teva Pharmaceutical and Chemical (Hangzhou) Co. Ltd. 4/5/17
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Teva Pharma Receive Warning Letter - Parker Waichman LLP
